Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE

NCT02130362 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02130362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02130362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
August 28, 2014
Completion date
November 30, 2030
Enrollment
1,446 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease